Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (9): 867-874.DOI: 10.3969/j.issn.1673-8640.2025.09.007
Previous Articles Next Articles
LIU Hao1, FU Miao2, LIU Peng2, TIAN Wen2, WANG Sha2, YIN Xiaomei2, WANG Donghai1
Received:
2023-12-03
Revised:
2024-11-25
Online:
2025-09-30
Published:
2025-09-30
CLC Number:
LIU Hao, FU Miao, LIU Peng, TIAN Wen, WANG Sha, YIN Xiaomei, WANG Donghai. Expressions and roles of WDR5 and miR-455-5p in cervical cancer patients[J]. Laboratory Medicine, 2025, 40(9): 867-874.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.09.007
项目 | 上游引物(5'~3') | 下游引物(5'~3') |
---|---|---|
WDR5 mRNA | GTGTGAGGATATGGGACGTGA | GAACGGCTGAGACTGGGTC |
GAPDH | GAGTCAACGGATTTGGTCGT | GACAAGATTCCCGTTCTCAG |
miR-455-5p | GCCGTATGTGCCTTTGGACT | GTGCAGGGTCCGAGGT |
U6 | CTCGCTTCGGCAGCACA | AACGCTTCACGAATTTGCGT |
项目 | 上游引物(5'~3') | 下游引物(5'~3') |
---|---|---|
WDR5 mRNA | GTGTGAGGATATGGGACGTGA | GAACGGCTGAGACTGGGTC |
GAPDH | GAGTCAACGGATTTGGTCGT | GACAAGATTCCCGTTCTCAG |
miR-455-5p | GCCGTATGTGCCTTTGGACT | GTGCAGGGTCCGAGGT |
U6 | CTCGCTTCGGCAGCACA | AACGCTTCACGAATTTGCGT |
组别 | 例数 | 年龄/岁 | BMI/(kg·m-2) | 产次/次 |
---|---|---|---|---|
宫颈癌组 | 78 | 44.51±7.59 | 23.11±4.17 | 1.72±0.61 |
CIN组 | 78 | 44.13±7.61 | 23.71±4.14 | 1.64±0.53 |
正常对照组 | 78 | 43.58±7.24 | 23.84±4.09 | 1.75±0.59 |
F值 | 0.305 | 0.692 | 0.756 | |
P值 | 0.738 | 0.501 | 0.471 |
组别 | 例数 | 年龄/岁 | BMI/(kg·m-2) | 产次/次 |
---|---|---|---|---|
宫颈癌组 | 78 | 44.51±7.59 | 23.11±4.17 | 1.72±0.61 |
CIN组 | 78 | 44.13±7.61 | 23.71±4.14 | 1.64±0.53 |
正常对照组 | 78 | 43.58±7.24 | 23.84±4.09 | 1.75±0.59 |
F值 | 0.305 | 0.692 | 0.756 | |
P值 | 0.738 | 0.501 | 0.471 |
组别 | 例数 | WDR5 mRNA | WDR5蛋白/(pg·mL-1) | miR-455-5p |
---|---|---|---|---|
宫颈癌组 | 78 | 1.61±0.43*# | 36.62±4.29*# | 0.75±0.21*# |
CIN组 | 78 | 1.29±0.21* | 32.98±3.95* | 0.91±0.18* |
正常对照组 | 78 | 1.00±0.29 | 18.34±2.18 | 1.01±0.27 |
F值 | 69.580 | 565.230 | 26.940 | |
P值 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | WDR5 mRNA | WDR5蛋白/(pg·mL-1) | miR-455-5p |
---|---|---|---|---|
宫颈癌组 | 78 | 1.61±0.43*# | 36.62±4.29*# | 0.75±0.21*# |
CIN组 | 78 | 1.29±0.21* | 32.98±3.95* | 0.91±0.18* |
正常对照组 | 78 | 1.00±0.29 | 18.34±2.18 | 1.01±0.27 |
F值 | 69.580 | 565.230 | 26.940 | |
P值 | <0.001 | <0.001 | <0.001 |
项目 | 例数 | WDR5 mRNA | miR-455-5p |
---|---|---|---|
年龄 | |||
≥50岁 | 37 | 1.60±0.44 | 0.76±0.20 |
<50岁 | 41 | 1.62±0.42 | 0.74±0.22 |
t值 | 0.205 | 0.418 | |
P值 | 0.838 | 0.677 | |
TNM分期 | |||
Ⅰ~Ⅱ期 | 43 | 1.47±0.29 | 0.82±0.14 |
Ⅲ~Ⅳ期 | 35 | 1.78±0.26 | 0.66±0.12 |
t值 | 4.916 | 5.347 | |
P值 | <0.001 | <0.001 | |
分化程度 | |||
高分化 | 35 | 1.44±0.25 | 0.84±0.11 |
中低分化 | 43 | 1.75±0.29 | 0.68±0.13 |
t值 | 4.991 | 5.786 | |
P值 | <0.001 | <0.001 | |
肿瘤最大直径 | |||
≥4 cm | 36 | 1.79±0.24 | 0.68±0.14 |
<4 cm | 42 | 1.46±0.28 | 0.81±0.15 |
t值 | 5.538 | 3.934 | |
P值 | <0.001 | <0.001 | |
浸润深度 | |||
≥1/2肌层 | 33 | 1.79±0.23 | 0.67±0.13 |
<1/2肌层 | 45 | 1.48±0.26 | 0.81±0.14 |
t值 | 5.458 | 4.496 | |
P值 | <0.001 | <0.001 | |
病理类型 | |||
腺癌 | 35 | 1.61±0.42 | 0.74±0.20 |
鳞癌 | 43 | 1.60±0.44 | 0.76±0.21 |
t值 | 0.102 | 0.427 | |
P值 | 0.919 | 0.670 | |
淋巴转移 | |||
有 | 40 | 1.77±0.25 | 0.67±0.13 |
无 | 38 | 1.44±0.27 | 0.84±0.12 |
t值 | 5.604 | 5.993 | |
P值 | <0.001 | <0.001 |
项目 | 例数 | WDR5 mRNA | miR-455-5p |
---|---|---|---|
年龄 | |||
≥50岁 | 37 | 1.60±0.44 | 0.76±0.20 |
<50岁 | 41 | 1.62±0.42 | 0.74±0.22 |
t值 | 0.205 | 0.418 | |
P值 | 0.838 | 0.677 | |
TNM分期 | |||
Ⅰ~Ⅱ期 | 43 | 1.47±0.29 | 0.82±0.14 |
Ⅲ~Ⅳ期 | 35 | 1.78±0.26 | 0.66±0.12 |
t值 | 4.916 | 5.347 | |
P值 | <0.001 | <0.001 | |
分化程度 | |||
高分化 | 35 | 1.44±0.25 | 0.84±0.11 |
中低分化 | 43 | 1.75±0.29 | 0.68±0.13 |
t值 | 4.991 | 5.786 | |
P值 | <0.001 | <0.001 | |
肿瘤最大直径 | |||
≥4 cm | 36 | 1.79±0.24 | 0.68±0.14 |
<4 cm | 42 | 1.46±0.28 | 0.81±0.15 |
t值 | 5.538 | 3.934 | |
P值 | <0.001 | <0.001 | |
浸润深度 | |||
≥1/2肌层 | 33 | 1.79±0.23 | 0.67±0.13 |
<1/2肌层 | 45 | 1.48±0.26 | 0.81±0.14 |
t值 | 5.458 | 4.496 | |
P值 | <0.001 | <0.001 | |
病理类型 | |||
腺癌 | 35 | 1.61±0.42 | 0.74±0.20 |
鳞癌 | 43 | 1.60±0.44 | 0.76±0.21 |
t值 | 0.102 | 0.427 | |
P值 | 0.919 | 0.670 | |
淋巴转移 | |||
有 | 40 | 1.77±0.25 | 0.67±0.13 |
无 | 38 | 1.44±0.27 | 0.84±0.12 |
t值 | 5.604 | 5.993 | |
P值 | <0.001 | <0.001 |
指标 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
WDR5 mRNA | 0.767(0.692~0.831) | 1.20 | 69.23 | 83.33 | 0.526 |
miR-455-5p | 0.756(0.680~0.821) | 0.84 | 66.67 | 84.62 | 0.513 |
联合检测 | 0.883(0.822~0.929) | 0.59 | 89.74 | 82.05 | 0.718 |
指标 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
WDR5 mRNA | 0.767(0.692~0.831) | 1.20 | 69.23 | 83.33 | 0.526 |
miR-455-5p | 0.756(0.680~0.821) | 0.84 | 66.67 | 84.62 | 0.513 |
联合检测 | 0.883(0.822~0.929) | 0.59 | 89.74 | 82.05 | 0.718 |
指标 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
WDR5 mRNA | 0.857(0.760~0.926) | 0.35 | 74.36 | 82.05 | 0.564 |
miR-455-5p | 0.798(0.692~0.880) | 0.31 | 66.67 | 84.62 | 0.513 |
联合检测 | 0.861(0.764~0.929) | 0.71 | 87.18 | 74.36 | 0.615 |
指标 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | 约登指数 |
---|---|---|---|---|---|
WDR5 mRNA | 0.857(0.760~0.926) | 0.35 | 74.36 | 82.05 | 0.564 |
miR-455-5p | 0.798(0.692~0.880) | 0.31 | 66.67 | 84.62 | 0.513 |
联合检测 | 0.861(0.764~0.929) | 0.71 | 87.18 | 74.36 | 0.615 |
项目 | 单因素Cox回归分析 | 多因素Cox回归分析 | |||
---|---|---|---|---|---|
HR①值(95%CI) | P值 | HR①值(95%CI) | P值 | ||
TNM分期(Ⅰ~Ⅱ期与Ⅲ~Ⅳ期) | 2.493(1.495~4.158) | <0.001 | 3.026(1.471~6.224) | 0.003 | |
肿瘤最大直径(<4 cm与≥4 cm) | 4.896(1.770~13.540) | 0.002 | 2.696(1.387~5.239) | 0.003 | |
浸润深度(<1/2肌层与≥1/2肌层) | 3.724(1.772~7.827) | <0.001 | 3.437(1.524~7.752) | 0.003 | |
分化程度(中低分化与高分化) | 3.681(1.861~7.281) | <0.001 | 4.479(1.582~12.682) | 0.005 | |
淋巴转移(无与有) | 5.937(1.821~19.358) | 0.003 | 5.024(2.084~12.113) | <0.001 | |
WDR5 mRNA(≥1.20与<1.20) | 6.140(1.712~22.048) | 0.005 | 4.261(2.035~8.921) | <0.001 | |
miR-455-5p(>0.84与≤0.84) | 0.493(0.300~0.811) | 0.005 | 0.553(0.393~0.776) | <0.001 |
项目 | 单因素Cox回归分析 | 多因素Cox回归分析 | |||
---|---|---|---|---|---|
HR①值(95%CI) | P值 | HR①值(95%CI) | P值 | ||
TNM分期(Ⅰ~Ⅱ期与Ⅲ~Ⅳ期) | 2.493(1.495~4.158) | <0.001 | 3.026(1.471~6.224) | 0.003 | |
肿瘤最大直径(<4 cm与≥4 cm) | 4.896(1.770~13.540) | 0.002 | 2.696(1.387~5.239) | 0.003 | |
浸润深度(<1/2肌层与≥1/2肌层) | 3.724(1.772~7.827) | <0.001 | 3.437(1.524~7.752) | 0.003 | |
分化程度(中低分化与高分化) | 3.681(1.861~7.281) | <0.001 | 4.479(1.582~12.682) | 0.005 | |
淋巴转移(无与有) | 5.937(1.821~19.358) | 0.003 | 5.024(2.084~12.113) | <0.001 | |
WDR5 mRNA(≥1.20与<1.20) | 6.140(1.712~22.048) | 0.005 | 4.261(2.035~8.921) | <0.001 | |
miR-455-5p(>0.84与≤0.84) | 0.493(0.300~0.811) | 0.005 | 0.553(0.393~0.776) | <0.001 |
[1] | MITCHELL K, SPROWLS S A, ARORA S, et al. WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma[J]. Genes Dev, 2023, 37(3):86-102. |
[2] |
PUNZI S, BALESTRIERI C, D'ALESIO C, et al. WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells[J]. Breast Cancer Res, 2019, 21(1):123.
DOI PMID |
[3] | 曾蒙颖, 雷鸣, 易碧云, 等. miR-455-5p在恶性肿瘤中作用机制的研究进展[J]. 中国现代医药杂志, 2021, 23(9):95-100. |
[4] | 中国抗癌协会妇科肿瘤专业委员会. 宫颈癌诊断与治疗指南(第四版)[J]. 中国实用妇科与产科杂志, 2018, 34(6):613-622. |
[5] |
BRYAN A F, WANG J, HOWARD G C, et al. WDR5 is a conserved regulator of protein synthesis gene expression[J]. Nucleic Acids Res, 2020, 48(6):2924-2941.
DOI PMID |
[6] | CAI W L, CHEN J F, CHEN H, et al. Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation[J]. Elife, 2022, 11:e78163. |
[7] | HUANG M, DONG W, XIE R, et al. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program[J]. Cancer Commun(Lond), 2022, 42(5):447-470. |
[8] | 赵福英. BAG3通过WDR5表观调控GALNT10表达促进顺铂耐药卵巢癌干细胞样特征[D]. 沈阳: 中国医科大学, 2022. |
[9] | SUN F, MO L, LAN Y, et al. WDR5 drives the development of cervical squamous cell carcinoma by inducing epithelial-mesenchymal transition and cancer-associated fibroblasts formation[J]. Pathol Res Pract, 2022, 238:154076. |
[10] | 宋珍珍. Circ_0072995在宫颈癌中的表达及通过miR-29a/WDR5对Hela细胞增殖和侵袭能力的影响[D]. 郑州: 郑州大学, 2022. |
[11] |
ALLES J, FEHLMANN T, FISCHER U, et al. An estimate of the total number of true human miRNAs[J]. Nucleic Acids Res, 2019, 47(7):3353-3364.
DOI PMID |
[12] | BOZGEYIK E, TEPE N B, BOZDAG Z. Identification of microRNA expression signature for the diagnosis and prognosis of cervical squamous cell carcinoma[J]. Pathol Res Pract, 2020, 216(11):153159. |
[13] | CHEN W, LI Q, ZHANG G, et al. LncRNA HOXA-AS3 promotes the malignancy of glioblastoma through regulating miR-455-5p/USP3 axis[J]. J Cell Mol Med, 2020, 24(20):11755-11767. |
[14] |
WU S, CAI W, LI Y, et al. SNHG3/hsa-miR-455-5p axis-mediated high expression of MTHFD2 correlates with tumor immune infiltration and endometrial carcinoma progression[J]. Int J Med Sci, 2023, 20(8):1097-1113.
DOI PMID |
[15] | 吕博文, 钱钧, 王杰, 等. miR-455-5p在上皮性卵巢癌中表达研究及其靶基因功能分析[J]. 实用肿瘤学杂志, 2019, 33(2):115-121. |
[16] |
HU D, SUN S, WANG Y. MicroRNA-455-5p exerts inhibitory effect in cervical carcinoma through targeting S1PR1 and blocking mTOR pathway[J]. Arch Gynecol Obstet, 2020, 301(5):1307-1315.
DOI PMID |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||